Rabbit Recombinant Monoclonal CFHR5 antibody. Carrier free. Suitable for Dot, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Dot | IP | Flow Cyt (Intra) | ICC/IF | IHC-P | WB | |
---|---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended | Tested |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Mouse, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH.
CFHL5, FHR5, CFHR5, Complement factor H-related protein 5, FHR-5
Rabbit Recombinant Monoclonal CFHR5 antibody. Carrier free. Suitable for Dot, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
CFHR5 also known as complement factor H-related protein 5 belongs to the complement system and affects immune response. CFHR5 has an approximate mass of 65 kDa. You can find it in plasma and tissues such as the liver and kidney. It plays a role in regulating the alternative complement pathway by interacting with various complement factors inhibiting excessive immune reactions.
CFHR5 regulates the complement system to prevent damage to host tissues. It does not commonly form complexes but interacts directly with other proteins in the complement system such as complement factor H. The balance maintained by CFHR5 is necessary to control inflammation and assist in removing pathogens without harming body's own cells.
The alternative complement pathway involves CFHR5 as a regulatory component. It ensures proper complement activation and prevents unregulated immune responses. CFHR5 engages with proteins such as complement factor H and C3b during pathway modulation. Changes in CFHR5 can impact the balance of immune activation and clearance of cellular debris within this pathway.
Mutations or malfunction of CFHR5 associate with certain kidney disorders such as CFHR5 nephropathy and atypical hemolytic uremic syndrome (aHUS). These conditions often link with dysregulation of the complement system. The relationship between CFHR5 and complement factor H is important in maintaining kidney function and avoiding disease development.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-CFHR5 antibody [EPR25711-28] ab305247, the same antibody clone in a different buffer formulation.
Dot blot analysis of CFHR5 using Anti-CFHR5 antibody [EPR25711-28] ab305247 at 1:1000 (0.507 ug/ml) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1:100,000 dilution.
Exposure time: 103 seconds.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Lane 1: His-tagged human CFHR1 recombinant fragment 10 ng
Lane 2: His-tagged human CFHR2 recombinant fragment 10 ng
Lane 3: His-tagged human CFHR3 recombinant fragment 10 ng
Lane 4: His-tagged human CFHR4 recombinant fragment 10 ng
Lane 5: His-tagged human CFHR5 recombinant fragment 10 ng
This antibody does not cross-react with human CFHR1, CFHR2, CFHR3 or CFHR4.
This data was developed using Anti-CFHR5 antibody [EPR25711-28] ab305247, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Negative control: human heart (Human Integrated Protein Expression Database-GeneCards).
Exposure time: 59 seconds.
All lanes: Western blot - Anti-CFHR5 antibody [EPR25711-28] (Anti-CFHR5 antibody [EPR25711-28] ab305247) at 1/1000 dilution
Lane 1: Human liver tissue lysate 20 μg
Lane 2: Human kidney tissue lysate 20 μg
Lane 3: Human heart tissue lysate 20 μg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Observed band size: 75 kDa
Exposure time: 59s
This data was developed using Anti-CFHR5 antibody [EPR25711-28] ab305247, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 180 seconds.
Observed MW (kDa): 64 (de-glycosylated form), 70 (glycosylated form).
All lanes: Western blot - Anti-CFHR5 antibody [EPR25711-28] (Anti-CFHR5 antibody [EPR25711-28] ab305247) at 1/1000 dilution
Lane 1: Untreated human plasma 20 μg
Lane 2: Human plasma treated with Protein Deglycosylation MIX II 20 μg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Observed band size: 64 kDa, 70 kDa
Exposure time: 180s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com